Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study - Poll - MDSpire

Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study

  • By

  • Lilan Zhao

  • Tianxing Guo

  • Yi Zhang

  • Zhen Huang

  • Yangyun Huang

  • Lihuan Zhu

  • Xing Chen

  • Nan Zhang

  • Liren Guo

  • Rongzhi Huang

  • Guojun Geng

  • Ning Li

  • Shuxing Chen

  • Xiaojie Pan

  • Wenshu Chen

  • October 24, 2025

  • 0 min

Share

Original Source(s)

Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study

  • by Lilan Zhao, Tianxing Guo, Yi Zhang, Zhen Huang, Yangyun Huang, Lihuan Zhu, Xing Chen, Nan Zhang, Liren Guo, Rongzhi Huang, Guojun Geng, Ning Li, Shuxing Chen, Xiaojie Pan, Wenshu Chen

  • October 24, 2025

Related Content

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate